阿托伐他汀联合依折麦布治疗急性冠脉综合征的临床效果分析

摘要

目的 研究阿托伐他汀联合依折麦布在治疗急性冠脉综合征(ACS)中的临床应用效果.方法 将本院在2012年1月至2015年12月期间收治的60例ACS患者分成对照组和联合治疗组,每组各30例,对照组患者给予口服阿托伐他汀,联合治疗组在对照组基础上加服依折麦布.比较两组的治疗效果.结果 ①与治疗前比较,两组血清TC、TG、LDL-C和hs-CRP均明显下降(P＜0.05),而联合治疗组下降幅度显著大于对照组(P＜0.05);治疗前后两组血清HDL-C水平无明显变化(P＞0.05);②治疗后,联合治疗组再发心绞痛和心肌梗死率显著低于对照组(P＜0.05).结论 阿托伐他汀联合依折麦布能够明显改善ACS患者血脂状况,减少心血管事件.%Objective To study clinical effect of atorvastatin combined with ezetimibe in the treatment of acute coronary syndrome (ACS).Methods 60 patients with ACS in our hospital from January 2012 to December 2015 were divided into control group and combined treatment group,30 cases in each group.Control group was treated with atorvastatin,combined treatment group was treated with atorvastatin and ezetimibe.The treatment effect of two groups was compared.Results Compared with before treatment,serum TC,TG,LDL-C,and hsCRP significantly decreased after treatment in both two groups (P＜0.05),and the descend range in combined treatment group was significantly greater than that in control group (P＜0.05);there was no statistically significant difference in serum HDL-C level before and after treatment in both two groups (P＞0.05).After treatment,the rates of recurrent angina and myocardial infarction in combined treatment group were significantly lower than those in control group (P＜0.05).Conclusion Atorvastatin combined with ezetimibe can significantly improve the blood lipid level of patients with ACS,reduce cardiovascular events.